2025

1. Su, L., Liu, S., Shi, L., Cheng, Y., Gao, J., Guo, R., He, Y., Zhang, L., Chen, T., Hu, J., Li, X., & Wang, Y. (2025). Dynamic alterations of circulating lymphocytes during the trajectory of Hantaan virus-induced hemorrhagic fever with renal syndrome. Frontiers in immunology, 16, 1567306.

2.Gao, D., Lv, Y., Hong, F., Wu, D., Wang, T., Gao, G., Lin, Z., Yang, R., Hu, J., He, A., & Zhang, P. (2025). Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma. Scientific reports, 15(1), 70.

2024

1. Zhai, M., Miao, J., Zhang, R., Liu, R., Li, F., Shen, Y., Wang, T., Xu, X., Gao, G., Hu, J., He, A., & Bai, J. (2024). KIF22 promotes multiple myeloma progression by regulating the CDC25C/CDK1/cyclinB1 pathway. Journal of cancer research and clinical oncology, 150(5), 239.

2023

1. Liu, R., Miao, J., Jia, Y., Kong, G., Hong, F., Li, F., Zhai, M., Zhang, R., Liu, J., Xu, X., Wang, T., Liu, H., Hu, J., Yang, Y., & He, A. (2023). N6-methyladenosine reader YTHDF2 promotes multiple myeloma cell proliferation through EGR1/p21^cip1/waf1/CDK2-Cyclin E1 axis-mediated cell cycle transition. Oncogene, 42(20), 1607–1619.

2022

1. Shang Y, Jin Y, Liu H, Ding L, Tong X, Tu H, Zang L, Lin C, Hu J, Zhou F. Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents. Hematol Oncol. 2022 Apr;40(2):212-222.

2021

1. Liu R, Shen Y, Hu J, Wang X, Wu D, Zhai M, Bai J, He A. Comprehensive Analysis of m6A RNA Methylation Regulators in the Prognosis and Immune Microenvironment of Multiple Myeloma. Front Oncol. 2021 Nov 4;11:731957. 
2. Wu D, Miao J, Hu J, Li F, Gao D, Chen H, Feng Y, Shen Y, He A. PSMB7 Is a Key Gene Involved in the Development of Multiple Myeloma and Resistance to Bortezomib. Front Oncol. 2021 Jul 23;11:684232.
3. Shen Y, Feng Y, Li F, Jia Y, Peng Y, Zhao W, Hu J, He A. lncRNA ST3GAL6-AS1 promotes invasion by inhibiting hnRNPA2B1 mediated ST3GAL6 expression in multiple myeloma. Int J Oncol. 2021 Apr;58(4):5.
4. Wang J, Xu Y, Zhang X, Wang S, Peng Z, Guo J, Jiang H, Liu J, Xie Y, Wang J, Li X, Liao J, Wan C, Yu L, Hu J, Liu B, Liu Z. Leptin correlates with monocytes activation and severe condition in COVID-19 patients. J Leukoc Biol. 2021 Jul;110(1):9-20. （新冠研究，亮点论文+述评）
5. Lei L, Zhang Y, Jian Q, Lei L, Lv N, Williamson RA, Chen P, Zhang D, Hu J. Resistance of osteosarcoma cells to the proapoptotic effects of carfilzomib involves activation of mitogen activated protein kinase pathways. Exp Physiol. 2021 Feb;106(2):438-449.
6. Zhang D, Guo R, Lei L, Liu H, Wang Y, Wang Y, Qian H, Dai T, Zhang T, Lai Y, Wang J, Liu Z, Chen T, He A, O'Dwyer M, Hu J. Frontline Science: COVID-19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytes. J Leukoc Biol. 2021 Jan;109(1):13-22. （新冠研究，亮点论文+述评）

2020

1. Zhang D, De Veirman K, Fan R, Jian Q, Zhang Y, Lei L, Evans H, Wang Y, Lei L, Wang B, Williamson RA, Chantry A, He P, Li A, De Raeve H, Vanderkerken K, He A, Hu J. ER stress arm XBP1s plays a pivotal role in proteasome inhibition-induced bone formation. Stem Cell Res Ther. 2020 Nov 30;11(1):516.
2. Teng R, Wang Y, Lv N, Zhang D, Williamson RA, Lei L, Chen P, Lei L, Wang B, Fu J, Liu X, He A, O'Dwyer M, Hu J. Hypoxia Impairs NK Cell Cytotoxicity through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways. J Immunol Res. 2020 Jun 19;2020:4598476.
3. Yang X, Dai T, Zhou X, Qian H, Guo R, Lei L, Zhang X, Zhang D, Shi L, Cheng Y, Hu J, Guo Y, Zhang B. Naturally activated adaptive immunity in COVID-19 patients. J Cell Mol Med. 2020 Nov;24(21):12457-12463.
4. Lei L, Qian H, Yang X, Zhang X, Zhang D, Dai T, Guo R, Shi L, Cheng Y, Zhang B, Zhou X, Hu J, Guo Y. The phenotypic changes of gamma-delta T cells in COVID-19 patients. J Cell Mol Med. 2020 Oct;24(19):11603-11606.
5. Zhang D, Teng R, Lv N, Lei L, Wang Y, Williamson RA, Chen P, Gao P, O'Dwyer M, Li A, Hu J. A novel CD2 staining-based flow cytometric assay for assessment of natural killer cell cytotoxicity. J Clin Lab Anal. 2020 Dec;34(12):e23519.
6. Zhang D, Teng R, Lv N, Lei L, Wang Y, Williamson RA, Chen P, Gao P, O'Dwyer M, Li A, Hu J. A novel CD2 staining-based flow cytometric assay for assessment of natural killer cell cytotoxicity. J Clin Lab Anal. 2020 Dec;34(12):e23519.
7. Wang H, Lei L, Hu J, Li Y. Oncostatin M upregulates Livin to promote keratinocyte proliferation and survival via ERK and STAT3 signalling pathways. Exp Physiol. 2020 Jul;105(7):1151-1158.
8. Peng Y, Li F, Zhang P, Wang X, Shen Y, Feng Y, Jia Y, Zhang R, Hu J, He A. IGF-1 promotes multiple myeloma progression through PI3K/Akt-mediated epithelial-mesenchymal transition. Life Sci. 2020 May 15;249:117503.
9. Huang L, Wang Y, Bai J, Yang Y, Wang F, Feng Y, Zhang R, Li F, Zhang P, Lv N, Lei L, Hu J, He A. Blockade of HSP70 by VER-155008 synergistically enhances bortezomib-induced cytotoxicity in multiple myeloma. Cell Stress Chaperones. 2020 Mar;25(2):357-367.
10. Huang LJ, Shen Y, Bai J, Wang FX, Feng YD, Chen HL, Peng Y, Zhang R, Li FM, Zhang PH, Lei XR, Xue F, Ma YP, Hu JS, He AL. High Expression Levels of Long Noncoding RNA Small Nucleolar RNA Host Gene 18 and Semaphorin 5A Indicate Poor Prognosis in Multiple Myeloma. Acta Haematol. 2020;143(3):279-288.
11. Sarkar S, Chauhan SKS, Daly J, Natoni A, Fairfield H, Henderson R, Nolan E, Swan D, Hu J, Reagan MR, O'Dwyer M. The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide. Cancer Immunol Immunother. 2020 Mar;69(3):421-434.

2019

1. Jia X, Zhao Q, Zhang Y, Dong Y, Lei L, Williamson RA, Lei Y, Tan X, Zhang D, Hu J. Identification of a Five-CpG Signature with Diagnostic Value in Thyroid Cancer. J Comput Biol. 2019 Dec;26(12):1409-1417.
2. Zhang D, Cui G, Sun C, Lei L, Lei L, Williamson RA, Wang Y, Zhang J, Chen P, Wang A, Fan R, Han S, Wang Y, Hu J. Hypoxia promotes osteosarcoma cell proliferation and migration through enhancing platelet-derived growth factor-BB/platelet-derived growth factor receptor-b axis. Biochem Biophys Res Commun. 2019 Apr 30;512(2):360-366.

2018 - 2010 （selected）

1. Zhu M, Tian Y, Zhang H, Ma X, Shang B, Zhang J, Jiao Y, Zhang Y, Hu J, Wang Y. Methylphenidate ameliorates hypoxia-induced mitochondrial damage in human neuroblastoma SH-SY5Y cells through inhibition of oxidative stress. Life Sci. 2018 Mar 15;197:40-45.
2. Hu J, Van Valckenborgh E, Dehui X, Menu E, De Raeve H, De Bruyne E, Xu S, Van Camp B, Handisides D, Hart CP, Vanderkerken K. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro. Mol Cancer Ther. 2013;12(9):1763-1773.  
3. Xu D, Hu J, Xu S, De Bruyne E, Menu E, Van Camp B, Vanderkerken K, Van Valckenborgh E. Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation. Leukemia. 2012;26(6):1402-5.      
4. Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R, hompson B, Maiso P, Sun JD, Hart CP, Roccaro AM, acco A, Ngo HT, Lin CP, Kung AL, Carrasco DR, Vanderkerken K, Ghobrial IM. Hypoxia promotes dissemination of multiple myeloma through acquisition of endothelial to mesenchymal transition-like features. Blood. 2012;119(24):5782-94.    
5. Xu D, Hu J, Bruyne ED, Menu E, Schots R, Vanderkerken K, Van Valckenborgh E. Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma. Biochem Biophys Res Commun. 2012;428(4):518-24.     
6. Xu S, Evans H, Buckle C, De Veirman K, Hu J, Xu D, Menu E, De Becker A, Vande Broek I, Leleu X, Camp BV, Croucher P, Vanderkerken K, Van Riet I. Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway. Leukemia. 2012;26(12):2546-9.
7. Hu J, Van Valckenborgh E, Menu E, De Bruyne E, Vanderkerken K. Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models. Dis Model Mech. 2012;5(6):763-71.            
8. Hu J, Dang N, Menu E, De Bryune E, Xu D, Van Camp B, Van Valckenborgh E, Vanderkerken K. Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition. Blood. 2012;119(3):826-37.    
9. Hu J, Dang N, Song T, Vanderkerken K. Mcl-1 reduction due to caspase-dependent cleavage during endoplasmic reticulum stress-induced apoptosis. J Biol Chem. 2011;286(44):le24.  
10. Hu J, Handisides DR, Van Valckenborgh E, De Raeve H, Menu E, Vande Broek I, Liu Q, Sun JD, Van Camp B, Hart CP, Vanderkerken K. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood. 2010;116(9):1524-7.